SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
To determine the activity of SCH 727965 in participants with breast cancer and in participants with nonsmall-cell lung cancer (NSCLC) compared to standard treatment. The standard treatment used is capecitabine for breast cancer and erlotinib for NSCLC. The study will also determine the activity of SCH 727965 treatment in participants who experience cancer progression after standard treatment.
Breast Neoplasms|Carcinoma, Non-Small-Cell Lung
DRUG: SCH 727965|DRUG: Capecitabine|DRUG: Erlotinib
Time to disease progression., Date of randomization to date of tumor progression., Every 6 weeks for 30 weeks, and then every 9 weeks. Assessments continue until disease progression.|Overall response rate in participants treated with SCH 727965 after disease progression on the comparator drug., Percentage of participants with tumor responses (partial responses + complete responses)., Every 6 weeks for 30 weeks, and then every 9 weeks.
To determine the activity of SCH 727965 in participants with breast cancer and in participants with nonsmall-cell lung cancer (NSCLC) compared to standard treatment. The standard treatment used is capecitabine for breast cancer and erlotinib for NSCLC. The study will also determine the activity of SCH 727965 treatment in participants who experience cancer progression after standard treatment.